EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Finerenone in Diabetic Chronic Kidney Disease—Real-World Insights Including Patients with HFpEF or HFmrEF

Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann-Kathrin Schäfer, Michael J Koziolek, Manuel Wallbach

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Kristian Hellenkamp und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany. Hauptthemen laut MEDLINE: Stroke Volume, Heart Failure, Naphthyridines, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Finerenone, a highly selective non-steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). This study aimed to investigate the safety and cardiac effects of finerenone in patients with DKD with or without HFpEF/HFmrEF in a real-world setting.

Methods

Patients with DKD were prospectively enrolled and were treated with finerenone according to best clinical practice. Clinical, laboratory and echocardiographic assessments were performed before, 4 weeks and 6 months after starting finerenone.

Results

Thirty-one patients with DKD were included. At baseline, patients had a typical risk profile with arterial hypertension (90.3%) and hyperlipoproteinemia (87.1%). Most patients were treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (93.5%). Treatment with finerenone was safe and well tolerated: after 4 weeks, the glomerular filtration rate decreased slightly from 52 (43–78) mL/min/1.73 m2 to 48.0 (39.0–71.0) mL/min/1.73 m2 (P = 0.002 vs. baseline), but stabilized thereafter. Similarly, the median potassium value increased from 4.2 (3.8–4.5) mmol/L to 4.4 (4.2–4.8) mmol/L (P = 0.017) after 4 weeks, but remained stable thereafter [4.4 (4.1–4.6) mmol/L (P = 0.079)]. Only one patient (3.2%) had an unplanned hospitalization and concomitant hyperkalaemia up to 6.0 mmol/L. HFpEF/HFmrEF was frequently found in patients with DKD (71.0%), although most patients had a rather early stage with only mild symptoms and a median N-terminal pro B-type natriuretic peptide (NT-proBNP) value of 150.8 (54.5–325.7) ng/L. During treatment with finerenone, NT-proBNP and left ventricular mass index (LVMI) remained stable. In contrast, left atrial volume index (LAVI) decreased from baseline [31.2 (26.8–39.7) mL/m2] to 4 weeks follow-up [29.7 (20.8–33.6) mL/m2, P = 0.027] and decreased further after 6 months [26.6 (20.8–34.9) mL/m2, P = 0.029]. In the subgroup of patients with HFpEF/HFmrEF, E/e′ decreased from 11.9 (8.7–14.5) at baseline to 9.9 (8.0–12.4) after 6 months (P = 0.043).

Conclusions

In a real-world setting, treatment with finerenone is safe and well-tolerated in patients with DKD and may improve functional and structural cardiac parameters. Further investigation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stroke VolumeHeart FailureNaphthyridinesRenal Insufficiency, ChronicDiabetic NephropathiesDiabetes Mellitus, Type 2Ventricular Function, LeftHumansMaleFemaleAgedProspective StudiesMineralocorticoid Receptor AntagonistsGlomerular Filtration RateMiddle AgedFollow-Up StudiesEchocardiographyTreatment Outcome

Stichwörter der Autor:innen

HFmrEFHFpEFchronic kidney diseasediabetic kidney diseasefinerenoneheart failure with preserved ejection fractionmineralocorticoid receptor antagonist

Substanzen

finerenoneMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany.
  • DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.
  • Department of Nephrology and Rheumatology, University Medical Centre Göttingen, Göttingen, Germany.
  • Department of Geriatrics, University Medical Centre Göttingen, Göttingen, Germany.
  • Department of Gastroenterology, gastrointestinal Oncology and Endocrinology, University Medical Centre Göttingen, Göttingen, Germany.

Zitieren

APA

Hellenkamp, K., Kaebe, S., Valentova, M., von Haehling, S., Delistefani, F., Gollisch, K., Raddatz, D., Schäfer, A. K., Koziolek, M. J., & Wallbach, M. (2025). Finerenone in Diabetic Chronic Kidney Disease—Real-World Insights Including Patients with HFpEF or HFmrEF. ESC Heart Failure. https://doi.org/10.1002/ehf2.15424

Vancouver

Hellenkamp K, Kaebe S, Valentova M, von Haehling S, Delistefani F, Gollisch K, et al. Finerenone in Diabetic Chronic Kidney Disease—Real-World Insights Including Patients with HFpEF or HFmrEF. ESC Heart Failure. 2025. doi:10.1002/ehf2.15424

BibTeX
@article{Hellenkamp2025,
  author = {Hellenkamp, Kristian and Kaebe, Sophia and Valentova, Miroslava and von Haehling, Stephan and Delistefani, Fani and Gollisch, Katja and Raddatz, Dirk and Schäfer, Ann-Kathrin and Koziolek, Michael J and Wallbach, Manuel},
  title = {Finerenone in Diabetic Chronic Kidney Disease—Real-World Insights Including Patients with HFpEF or HFmrEF},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15424}
}
Kostenlos starten →